Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chinese Bulk Aspirin Sales Below Fair Value In U.S. -ITA

This article was originally published in The Tan Sheet

Executive Summary

Bulk aspirin imported from the People's Republic of China (PRC) is being, or is likely to be, sold in the U.S. at less than fair value margins ranging up to 144%, the International Trade Administration says in a preliminary determination published in the Federal Register Jan. 3.

You may also be interested in...

Chinese Aspirin "Dumping" Is Under Trade Commission Investigation

The International Trade Commission is instituting an investigation into evidence of possible Chinese aspirin "dumping" onto the U.S. market, the commission announced in the Federal Register June 7. The investigation follows a May 28 petition from bulk aspirin manufacturer Rhodia requesting the "imposition of antidumping duties on imports of bulk aspirin from the People's Republic of China."

U.S. Creatine Industry "Materially Injured" By Chinese Importation - ITC

Creatine imported from Chinese companies selling the dietary supplement ingredient below fair market prices poses a material threat to U.S. creatine producers, the U.S. International Trade Commission determines in an April preliminary investigation report.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts